Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

You may be eligible if

• All patients must have histologically or cytologically documented non-small cell carcinoma of the lung (adenocarcinoma, large cell, squamous, or mixtures of these types)
• Patients with stage IV disease are eligible
• Documentation of PS 2 must be noted on form C-1392
• Patients must have measurable or non-measurable disease
• Measurable disease (target lesions): lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan
• Non-measurable disease (non-target lesions): all other lesions, including small lesions (longest diameter \< 20 mm with conventional techniques or \< 10 mm with spiral CT scan) and truly nonmeasurable lesions; lesions that are considered non-measurable include the following:
• * Bone lesions
• * Ascites
• * Pleural/pericardial effusion
• * Lymphangitis cutis/pulmonis
• * Abdominal masses that are not confirmed and followed by imaging techniques
• * Cystic lesions
• No prior systemic treatment for advanced NSCLC is permitted; prior treatment for early-stage disease (adjuvant) or for locally-advanced stage III disease is allowed if completed at least 12 months prior to registration
• Patients must have recovered (all toxicities ≤ grade 1) from prior surgery and/or radiotherapy
• No prior therapy which specifically and directly targets the EGFR pathway
• No prior severe infusion reactions to a monoclonal antibody
• No ≥ grade 2 peripheral neuropathy
• Non-pregnant and non-nursing
• No concurrent treatment with any other investigational therapy
• Granulocytes ≥ 1,500/μl
• Platelets ≥ 100,000/μl
• Serum creatinine ≤ ULN
• Bilirubin ≤ ULN
• AST ≤ ULN